Resilience, a technology-forward contract development and manufacturing organization dedicated to broadening access to complex medicines, has announced an expansion of its strategic partnership with Eli Lilly and Company aimed at increasing U.S. medicine production through new pharmaceutical manufacturing investments in Ohio. The latest development builds on the collaboration first established in 2023 and marks another step in the companies’ efforts to expand advanced manufacturing capabilities in the state.
Under the joint $750 million investment by Resilience and Lilly, Resilience’s manufacturing operations in the Cincinnati region will now include production of Lilly’s KwikPen injectable device for innovative medicines used in the treatment of diabetes and obesity. The expansion is expected to generate at least 400 new high-skilled jobs, increasing the total number of Resilience-created jobs in Ohio to more than 1,400 across its facilities. Preparatory work at the expanded campus has already begun, while full operations are scheduled to begin in early 2027.
“We are proud of what we have built together with Lilly and this new expansion as we scale production of complex medicines in Ohio,” said William S. Marth, President and Chief Executive Officer of Resilience.
“Our investment reflects our long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging operations in the United States, and demonstrates how trusted partnerships, operational excellence, and disciplined execution can strengthen America’s medicine supply,” he added.
Partnership Continues to Expand Domestic Manufacturing Capacity
The long-term manufacturing collaboration between Lilly and Resilience has already resulted in the production of more than 150 million doses of medicines for patients across the United States in vial and pre-filled syringe formats. Together, the organizations have established one of the nation’s largest sterile injectable manufacturing operations, highlighting how trusted U.S. manufacturing partnerships can scale production while maintaining high standards of quality, reliability, and execution. This continued investment also reflects the growing importance of U.S. medicine production as manufacturing capabilities expand to meet rising demand for critical therapies.
Edgardo Hernandez, Lilly’s Executive Vice President and President, Manufacturing Operations, added, “As demand for our medicines continues to increase, scaling complex manufacturing programs requires proven technical capability, an uncompromising commitment to quality, and the ability to deliver consistently over time. Today’s announcement highlights Resilience’s role as a strong partner to Lilly in strengthening domestic supply of high-demand treatments.”
“Resilience is an example of Ohio’s emerging leadership in biomanufacturing,” said Ohio Governor Mike DeWine.
Resilience currently operates two advanced facilities in the Cincinnati region that together span nearly 1 million sq. ft. and employ nearly 1,000 Resilience team members across manufacturing, operations, quality, and regulatory functions. The company also recently established its Blue Ash, Ohio location as its global headquarters, underscoring its long-term commitment to the state. The latest announcement also reflects Resilience’s expanding presence in U.S. pharmaceutical manufacturing and its ongoing investment in U.S. medicine production through manufacturing growth in Ohio. In addition, the company’s collaboration with JobsOhio, REDI Cincinnati, and Ohio Life Sciences (OLS) has supported the development of a strong pipeline of high-skilled manufacturing talent across the Cincinnati region.
